Photo from wikipedia
The prognostic value of ribonucleotide reductase M1 (RRM1) in patients with pancreatic cancer receiving gemcitabine chemotherapy has been evaluated in several studies. However, the conclusions remain controversial. Click to show full abstract
The prognostic value of ribonucleotide reductase M1 (RRM1) in patients with pancreatic cancer receiving gemcitabine chemotherapy has been evaluated in several studies. However, the conclusions remain controversial.
Keywords:
gemcitabine chemotherapy;
cancer receiving;
pancreatic cancer;
patients pancreatic;
receiving gemcitabine;
ribonucleotide reductase
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!